- May 13, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Pemfexy, Alimta
Synonyms :
pemetrexed
Class :
Antineoplastics, Antimetabolite
Dosage forms & Strengths:
Adult:
Injection/lyophilized powder for reconstitution
100 mg/vial
500 mg/vial
Injectable solution:
100 mg/4ml
500 mg/20 ml
850 mg/34 ml
1000 mg/40 ml
21-day cycle for metastatic bladder & cervical cancer:
500
mg
Intravenous (IV)
on the first day of the cycle, repeat the cycle until disease progression
malignant pleural mesothelioma
21-day cycle (in combination with cisplatin):
500
mg/m^2
pemetrexed with cisplatin IV on the first day of the cycle, repeat the cycle until disease progression
Combination therapy
:
500
mg/m^2
Intravenous (IV)
pemetrexed on day 1 of a 21-day cycle in combination with pembrolizumab and platinum therapy for 4 cycles
500 mg/m2 IV pemetrexed on day 1 of a 21-day cycle in combination with cisplatin for up to 6 cycles
Single-agent therapy:
500 mg/m2 pemetrexed IV on day 1 of 21-day cycle continue until disease progression or unacceptable toxicity
Safety and efficacy are not seen in pediatrics
Refer to adult dosing
may have an increased neutropenic effect when combined with deferiprone
may have an increased myelosuppressive effect when combined with ropeginterferon alfa-2b
may enhance the serum concentration when combined with pemetrexed
may increase the Myelosuppressive effect of each other when combined
It may increase pemetrexed toxicities by increasing the serum concentration. Avoid aspirin from the 2 days before, through the treatment, and after 2 days.
avoid the combination as it may increase nephrotoxicity
increases toxicities such as myelosuppression, renal toxicity, and GI toxicity
may enhance myelosuppressive toxicity of pemetrexed
high-risk for serious infections due to increasing immunosuppression
may increase toxic adverse effects of pemetrexed
increases serum concentration and toxic effect on GI, avoid the combination
increases serum concentration and toxic effect on GI, avoid the combination
increases serum concentration and toxic effect on GI, avoid the combination
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
increases the serum level of pemetrexed
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
avoid palifermin during pemetrexed therapy and before and after 24 hours of treatment
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
increase toxic adverse effects and immunosuppression
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
myelosuppressive agents may diminish the therapeutic effect of BCG
may increase the level of each other by an unknown mechanism
may have an increased myelosuppressive effect when combined with fexinidazole
interaction may raise the risk of serious infections due to immunosuppressive effects
may diminish the therapeutic effect of brincidofovir
may diminish the therapeutic effect of the covid-19 vaccine
pemetrexed may enhance the immunosuppressive effect of inebilizumab
pemetrexed may decrease the therapeutic effects of lenograstim, avoid within 24 hours of administration of antineoplastic agents
may increase the serum concentration of oat1/3 substrates
may enhance the immunosuppressive effects of ocrelizumab
may enhance the immunosuppressive effects of pemetrexed
myelosuppressive agents may enhance adverse myelosuppressive effects of olaparib
pemetrexed may diminish the therapeutic effects of pidotimod
may enhance adverse myelosuppressive effects
may enhance the adverse toxic effects of pemetrexed
myelosuppressive Agents may enhance the adverse/toxic effect of clozapine
myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib
myelosuppressive Agents may enhance the neutropenic effect of deferiprone
may enhance the effect of myelosuppressive agents
may enhance the effect of myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with olaparib
may have an increased adverse effect when combined with clozapine
may have an increased adverse effect when comb
may decrease the therapeutic effect when combined with BCG vaccine
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may increase the toxic effect of myelosuppressive agents
>10%:
Nausea
Vomiting
Neutropenia
Fatigue
Anemia
Thrombocytopenia
Stomatitis/pharyngitis
Anorexia
Diarrhea
Rash
Constipation
Alopecia
Elevated creatinine
1-10%:
Fatigue
Thrombocytopenia
Anemia
Dehydration
Diarrhea
Nausea
Stomatitis/pharyngitis
Increased ALT
Anorexia
Rash
Alopecia
Constipation
Anorexia
Increased AST
<1%:
Supraventricular arrhythmias
Motor neuropathy
Renal failure
Pemetrexed is contraindicated in patients hypersensitive to the active ingredient.
Pregnancy consideration:
The drug is not safe for the fetus if administered during pregnancy.
Breastfeeding warnings:
No data is available regarding the secretion of the drug in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: pemetrexed
Pronounced: peh-meh-TREKS-ed
Why do we use pemetrexed?
Pemetrexed is used to treat mesothelioma and Non-Squamous-Non-Small Cell Lung Carcinoma.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
